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Background: Group I metabotropic glutamate receptors (mGluR) are coupled via Gαq/11 to the activation of
phospholipase Cβ, which hydrolyzes membrane phospholipids to form inositol 1,4,5 trisphosphate and
diacylglycerol. In addition to functioning as neurotransmitter receptors to modulate synaptic activity, pathological
mGluR5 signaling has been implicated in a number of disease processes including Fragile X, amyotrophic lateral
sclerosis, multiple sclerosis, Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, epilepsy, and drug
addiction. The expression of mGluR5 in astrocytes has been shown to be increased in several acute and chronic
neurodegenerative conditions, but little is known about the functional relevance of mGluR5 up-regulation in
astrocytes following injury.
Results: In the current study, we investigated primary mouse cortical astrocyte cell death in response to oxygen
glucose deprivation (OGD) and found that OGD induced both necrotic and apoptotic cell death of astrocytes. OGD
resulted in an increase in astrocytic mGluR5 protein expression, inositol phosphate formation and extracellular
regulated kinase (ERK1/2) phosphorylation, but only inositol phosphate formation was blocked with the mGluR5
selective antagonist MPEP. Cortical astrocytes derived from mGluR5 knockout mice exhibited resistance to OGD-
stimulated apoptosis, but a lack of mGluR5 expression did not confer protection against necrotic cell death. The
antagonism of the inositol 1,4,5 trisphosphate receptor also reduced apoptotic cell death in wild-type astrocytes,
but did not provide any additional protection to astrocytes derived from mGluR5 null mice. Moreover, the
disruption of Homer protein interactions with mGluR5 also reduced astrocyte apoptosis.
Conclusion: Taken together these observations indicated that mGluR5 up-regulation contributed selectively to the
apoptosis of astrocytes via the activation of phospholipase C and the release of calcium from intracellular stores as
well as via the association with Homer proteins.
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Several neurotransmitter receptors are expressed in
astrocytes including the G protein-coupled receptors
(GPCRs) for the excitatory neurotransmitter glutamate.
The metabotropic glutamate receptors (mGluRs) com-
prise the family C of GPCRs, which are characterized by
sequence similarities in their seven transmembrane
spanning helical domains and large extracellular amino-
terminal venus fly trap domain [1-3]. Eight distinct
mGluRs have been identified and are divided into three
subgroups based on sequence homology and G protein
coupling-specificity. Group I mGluRs (mGluR1 and
mGluR5) are predominantly coupled to the activation of
phospholipase C (PLC) via Gαq/11, whereas Group II
(mGluR2 and mGluR3) and Group III (mGluR4,
mGluR6, mGluR7 and mGluR8) mGluRs negatively
regulate adenylyl cyclase via Gαi. Group I mGluR stimu-
lation leads to Gαq/11-mediated intracellular activation
of second messenger pathways, βγ activation of ion
channels, as well as stimulation of G protein-
independent pathways [2-4]. Pharmacological and bio-
chemical experiments have shown that mGluR5 is the
predominant group I mGluR subtype expressed in cul-
tures of brain astrocytes [5,6] although mGluR1 is also
expressed in astrocytes in the spinal cord [7].
Astrocytic mGluR5 has been shown to play key roles
in glia-neuron interactions, regulation of glutamate re-
uptake, and the coupling of the neurovasculature to
neuronal activity [8-10]. However, the roles of mGluR5
in both astrocytic and neuronal survival following injury
are poorly understood. In neurons, Group I mGluRs
have been reported to both protect against and exacer-
bate cell death, depending on the model of toxicity
employed, the neuronal subtype involved, and prior acti-
vation state of the receptors themselves [11-17]. The
variety of signaling pathways activated by mGluR1/5
may explain these observations. Group I mGluRs
coupled to Gαq/11 proteins stimulate the activation of
PLC resulting in diacylglycerol and inositol-1,4,5-tri-
phosphate (InsP3) formation. By interacting with InsP3
receptors, InsP3 induces calcium release from intracellu-
lar stores potentially leading to inappropriate cell death
[18]. On the other hand, mGluR1/5 stimulation also
leads to activation of other signaling pathways important
for cell survival/proliferation, such as extracellular
signal-regulated kinases 1/2 (ERK1/2) and AKT [19,20].
Consistent with these opposing effects on cell survival,
the mGluR1/5 scaffold protein Homer has been shown
to promote the activation of both pro- and anti-survival
signaling pathways [19,21].
Group I mGluR expression is up-regulated in models
of epilepsy, brain injury, amyotrophic lateral sclerosis,
and multiple sclerosis [22-25]. Alterations in glutamate
signaling are also known to play a prominent role inischemic brain injury and both apoptotic and necrotic
astrocytes have been observed following in vivo ischemic
insults [26-30]. However, very little is known about the
functional consequences of elevated mGluR5 expression
on astrocyte survival following injury. Therefore, in the
present study, we utilized an in vitro model of ischemia/
reperfusion, oxygen glucose deprivation (OGD), to
evaluate the potential role of alterations in mGluR5 pro-
tein expression following the injury of astrocytes. We
find that OGD induces astrocytic cell death by both
apoptotic and necrotic mechanisms and results in a
rapid increase in mGluR5a expression that is independ-
ent of gene transcription. The observed OGD-induced
apoptotic cell death is associated with increased
mGluR5-dependent inositol phosphate formation and is
reduced in astrocytes isolated from mGluR5 knockout
mice. Moreover, OGD-induced apoptotic death of cor-
tical astrocytes was reduced following IP3 receptor an-
tagonism and Tat-Homer peptide-mediated interference
of Homer interactions with mGluR5. Taken together,
these observations indicate that upregulation of mGluR5
expression contributes to OGD-induced cell death via a
Gαq/11 and Homer mediated mechanism.
Results
OGD induces both necrotic and apoptotic cell death of
cortical asrtocytes
To assess the effects of OGD on cortical astrocyte cell
death, primary CD1 mouse cortical astrocytic cultures
were subjected to an in vitro model of OGD to mimic is-
chemia (no oxygen and no glucose) for periods varying
from 0 to 24 h followed by a 24 h reperfusion period
(normal oxygen and glucose conditions). Under these
conditions, astrocytes survived OGD treatment for 6 h
(Figure 1A). However, further incubation without glu-
cose and oxygen (12-24 h) led to a decrease in metabolic
activity (Figure 1A). Both necrotic cell death as mea-
sured by the release of LDH by the dying astrocytes
(Figure 1B) and apoptotic cell death as indicated by
chromatin condensation observed in Hoechst-stained
nuclei (Figure 1C) was induced following a 24 h OGD
exposure time (Figure 1D). Thus, the reduction in astro-
cytes viability in response to OGD was associated with a
mix of necrotic and apoptotic astrocytic cell death.
OGD-induced increase in mGluR5 protein expression
correlates with an increase in mGluR5-dependent inositol
phosphate signaling
Cortical mouse astrocytes primarily express mGluR5a
[5,6] and Group I mGluR expression have been previ-
ously shown to be up-regulated in models of brain in-
jury, epilepsy, amyotrophic lateral sclerosis, and multiple
sclerosis [22-25]. Therefore, we examined whether
mGluR5a protein expression was altered following OGD
Figure 1 OGD induces both necrotic and apoptotic cell death in cultured cortical astrocytes. A) Cell viability of cultured cortical astrocytes,
as assessed by the metabolic MTT assay following 0-24 h OGD followed by 24 h reperfusion. B) Necrotic cell death measured by lactate
dehydrogenase (LDH) assay following 0-24 h OGD followed by 24 h reperfusion. C) Representative photomicrographs of primary CD1 cortical
astrocytes cultures that were OGD treated for 0, 12, and 24 hours followed by 24 h reperfusion and stained with Hoescht dye to reveal cells
dying by apoptosis as evidenced by condensed chromatin/ pyknotic nuclei. D) Quantification of apoptotic CD1 astrocytic cell death following 0-
24 h OGD followed by 24 h reperfusion. All data represents the mean ± SD of 5 independent experiments and were analyzed by ANOVA
followed by Dunnet’s post-hoc testing, * p<0.05 versus untreated control cultures.
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determined by immunoblotting for mGluR5a, the levels
of mGluR5a expression in astrocytic cultures was not
detectable by immunoblot in primary CD1 mouse cor-
tical astrocytes, but OGD treatment (2-12 h) resulted in
increased mGluR5a expression (Figure 2A and B). How-
ever, the increase in mGluR5a expression was not corre-
lated with an increase in mGluR5a mRNA expression as
determined by RT-PCR (Figure 2C) suggested that either
mGluR5 turnover or mGluR5 protein translation was
altered as a consequence of OGD.
OGD-induced increase in mGluR5 protein expression
correlates with an increase in mGluR5-dependent inositol
phosphate signaling
Because mGluR5a protein expression was increased by
OGD, we assessed whether mGluR5-dependent inositol
phosphate (InsP) formation and ERK1/2 phosphoryl-
ation was altered in response to OGD. As shown in
Figure 3A, InsP formation in cortical astrocytes follow-
ing 4 h OGD was significantly increased compared to
non-ischemic cultures (0 h OGD). The observed in-
crease in InsP formation in response to OGD wasblocked by treating the astrocytic cultures with the
mGluR5-specific inverse agonist MPEP (100 μM)
(Figure 3A). OGD treatment of cortical astrocyte cul-
tures for increasing periods of time (3-24 h) resulted in
a treatment and time-dependent increase in ERK1/2
phosphorylation (Figure 3B). However, unlike what was
observed for InsP formation following OGD, MPEP
treatment (100 μM) of the astrocytic cultures did not in-
hibit OGD-induced increases in ERK1/2 phosphoryl-
ation (Figure 3C). These data suggested that the
mGluR5 receptors induced by OGD contributes to
increased InsP formation, but that increases in ERK1/2
activity induced by OGD likely occurred independently
of mGluR5.
mGluR5 promotes apoptotic, but not necrotic astrocytic
cell death
To investigate the selective contribution of mGluR5 to
either necrotic and/or apoptotic cell death induced by
OGD, we exposed cortical astrocytes derived from either
wild-type (mGluR5+/+) or mGluR5 knock-out
(mGluR5-/-) mice to OGD for 6-24 h. Apoptotic cell
death induced by OGD treatment was reduced in
Figure 2 mGluR5a protein expression is increased in cortical
astrocytic cultures in response to OGD. A) Representative
immunoblot showing increases in mGluR5a protein expression at 0,
2, 4, 6, and 12 h following OGD treatment. B) Quantification of
mGluR5a protein expression in primary CD1 mouse cortical
astrocytes following 0-12 h OGD. Data is normalized to mGluR5a
protein expression at 2 h. Data represents the mean ± SD of 4
independent experiments. C) Real time RT-PCR analysis shows no
significant change in mGluR5 mRNA levels in cortical astrocytes after
OGD. mGluR5 mRNA levels were normalized to mitochondrial S12
transcript levels and data represents mean ± SD from three
independent experiments.
Figure 3 Effect of OGD on InsP formation and ERK1/2
phosphorylation in cortical astrocytes. A) Inositol phosphate
(InsP) formation in primary CD1 mouse cortical astrocytes prior to
(Ctrl) and following OGD for 4 h in the presence and absence of the
mGluR5 inverse agonist MPEP (100 μM). Bonferroni post-hoc tests
were performed on three independent experiments (* p<0.05).
B) Representative phosph-ERK1/2, total ERK1/2 and actin blots of
primary CD1 mouse cortical astrocytes following 0-24 h OGD
followed by 24 h reperfusion treated in the absence and presence
of the mGluR5 inverse agonist MPEP (100 μM). C) Quantification of
ERK1/2 phosphorylation in primary CD1 mouse cortical astrocytes
following 0-24 h OGD followed by 24 h re-oxygenation treated in
the absence and presence of the mGluR5 inverse agonist MPEP
(100 μM). Data was normalized to total ERK1/2 protein expression.
Data represents the mean ± SD of 4 independent experiments.
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stained condensed nuclei (Figure 4A). A two way
ANOVA analysis demonstrated that the two genotypes
were responding differently to OGD treatment for 6-
24 h followed by a 24 h reperfusion treatment
(Figure 4B). Specifically, the mGluR5 null genetic back-
ground provided significant protection against OGD-
mediated apoptosis (Figure 4B). OGD treatment also
Figure 4 OGD-mediated apoptotic and necrotic cell death in wild
type and mGluR5 null cortical astrocytes. A) Photomicrographs of
primary cortical astrocytes derived from wild-type C57BL/6 (mGluR+/+)
and mGluR5 knockout (mGluR5-/-) littermate embryos that were OGD
treated for 0, 12, and 24 hours followed by 24 h re-oxygenation
and stained with Hoescht dye to reveal cells dying by
apoptosis as evidenced by condensed chromatin/pyknotic
nuclei. B) Quantification of apoptotic death of astrocytes
derived from mGluR5-/- and mGluR5+/+ embryos in response
to 0-24 h OGD followed by 24 h re-oxygenation. Data represent
the mean ± SD of 5-8 independent experiments. C) Necrotic
cell death measured by LDH assay following 0-24 h OGD
followed by 24 h re-oxygenation in cortical astrocytes derived
from mGluR5-/- and mGluR5+/+ embryos. Data represent the
mean ± SD of 4-7 independent experiments. Data were analyzed
by ANOVA followed by Dunnet’s post-hoc testing, * p<0.05
versus untreated control cultures.
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measured by increased LDH release (Figure 4C). How-
ever, necrotic astrocytic cell death in response to OGD
was not attenuated in cortical mouse cultures derived
from mGluR5-/- mouse embryos (Figure 4C). Taken to-
gether, these observations suggested a role for mGluR5
signaling in apoptotic, but not necrotic, astrocyte cell
death following OGD.
OGD induced apoptosis requires mGluR5-dependent
InsP3 receptor activation
To further delineate whether the observed increase in
InsP formation in response to OGD was dependent
upon mGluR5 expression, we tested whether the antag-
onism of the IP3 receptor with the InsP3 receptor-
specific inhibitor Xestospongin C would alter OGD
induced apoptosis of astrocytes derived from wild-type
and mGluR5-/- embryos. We found that Xestospongin C
treatment significantly reduced the apoptotic cell death
of wild-type astrocytes following 12 h of OGD treat-
ment, but did not affect OGD-induced apoptosis of
astrocytes derived from mGluR5-/- mice (Figure 5A).
Furthermore, as shown previously (Figure 4B), the
OGD-induced apoptosis of mGluR5-/- astrocytes was
significantly reduced when compared to wild-type cul-
tures and was not significantly different from wild-type
cultures treated with Xestospongin C (Figure 5A). In
contrast, the OGD time-dependent increase in ERK1/2
phosphorylation was not attenuated in astrocytic cul-
tures derived from mGluR5-/- mice (Figure 5B and C).
Taken together, these results further support the
pharmacological data indicating that mGluR5 contribu-
ted to OGD-induced apoptosis as the consequence of
InsP3 receptor activation, but does not contribute to
increases in ERK1/2 phosphorylation.
Role for Homer in OGD mediated astrocytic cell death
It has been suggest that Homer proteins may regulate the
efficiency of mGluR5-mediated activation of the InsP3 re-
ceptor [21], therefore we tested whether the treatment of
astrocytes with a cell permeable Tat-tagged peptide corre-
sponding to the mGluR5 Homer binding domain (Homer
peptide) would attenuate OGD-induced astrocytic cell
death [19]. Human embryonic kidney (HEK 293) cells
were transfected with Flag-mGluR5a and Homer 1b to
confirm that the Homer peptide disrupted mGluR5a/
Homer 1b interactions by co-immunoprecipitation. We
found that treatment of transfected HEK 293 cells with
Homer peptide (35 μM), but not a scrambled peptide for
1 h antagonized the co-immunoprecipitation of Homer 1b
with Flag-mGLuR5a (Figure 6A). Subsequently, the treat-
ment of primary mouse cortical astrocytes with Homer
peptide resulted in the reduction of astrocytic apoptotic
cell death, when compared to astrocytes treated with
Figure 5 Contribution of mGluR5 expression to OGD-induced
InsP formation and ERK1/2 phosphorylation. A) Quantification
of apoptotic death of astrocytes derived from mGluR5-/- and
mGluR5+/+ embryos in absence (DMSO) and presence 3 μM of
the selective IP3 receptor inhibitor Xestospongin C (XC) in
response to 12 h OGD followed by 24 h re-oxygenation.
Bonferroni post-hoc test was performed on three independent
experiments,* p<0.05 versus mGluR5+/+ DMSO treated control.
B) Representative phosph-ERK1/2, total ERK1/2 and actin blots of
primary mouse cortical astrocytes derived from mGluR5+/+ (+)
and mGluR5-/- (-) embryos following 0-24 h OGD followed by
24 h re-oxygenation treated. C) Quantification of ERK1/2
phosphorylation in primary mouse cortical astrocytes derived
from mGluR5+/+ (+) and mGluR5-/- (-) embryos following 0-24 h
OGD followed by 24 h re-oxygenation treated. Data was
normalized to total ERK1/2 protein expression. Data represents
the mean ± SD of 4 independent experiments.
Figure 6 Effect of disrupting mGluR5/Homer interactions on
OGD-induced astrocytic cell death. A) Representative immunoblot
of Homer1b co-immunoprecipitation with Flag mGluR5a from HEK
293 cells transfected with plasmid cDNAs encoding Homer 1b
(1 μg) and Flag-mGluR5a (3 μg) and treated with and without
Homer (35 μM) and scrambled (35 μM) Tat-tagged peptides for
1 h. B) Quantification of apoptotic CD1 astrocytic cell death
following 12 OGD and 24 h re-oxygenation following the
treatment of the astrocytic cultures during the OGD period with
Homer and scramble tat-tagged peptides (35 μM). Data represents
the mean ± SD of 6 independent experiments. Asterisks represent
significant differences by students t test, p<0.05.
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interactions appeared to also contribute to mGluR5-
mediated apoptotic cell death following OGD treatment.
Discussion
In the present study, we show that OGD induces both
apoptotic and necrotic astrocytic cell death. We find that
similar to what is observed for both acute and chronic
neurodegenerative conditions, such as pain, amyo-
trophic lateral sclerosis, multiple sclerosis, and epilepsy
[22-25,31-33] OGD also results in an increase in
mGluR5a expression. We find InsP formation in cortical
astrocytes is increased following OGD and that the treat-
ment of cultures with the mGluR selective antagonist
MPEP, not only attenuates OGD-mediated InsP forma-
tion, but the genetic deletion of mGluR5 selectively pro-
tects against OGD-induced apoptosis. The effects of
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signaling pathway, but appear to be associated with
increased signaling via the PLC-InsP3-calcium pathway
and Homer protein interactions.
We show that the mGluR5a expressed in response to
injury are functional and activated after the ischemic in-
sult. Group I mGluRs are known for their high constitu-
tive and agonist-independent activity when they are
overexpressed in heterologous systems [34]. However, in
this case, because OGD-induced mGluR5 expression in
astrocytes is not as high as those found in neuronal cul-
tures or in transfected cells [20], increased mGluR5 ac-
tivity may also be due to glutamate released by
astrocytes in response to ischemia. Indeed, ischemic
conditions could result in glutamate release by astro-
cytes through a variety of mechanisms [35]. The
observed increases in InsP formation following OGD are
consistent with previous work demonstrating that OGD
results in increased InsP formation, likely via a metabo-
tropic glutamate receptor [36].
We observe that OGD treatment activates a time-
dependent increase in ERK1/2 phosphorylation that
appears to be independent of mGluR5 activity, as
increases in ERK1/2 phosphorylation were not antago-
nized by treatment of cultures with the mGluR5 select-
ive antagonist MPEP. Furthermore, the genetic deletion
of the mGluR5 gene did not result in diminished ERK1/
2 phosphorylation in response to OGD. Indeed, in con-
trast to the InsP3 pathway, the mGluR5-induced activa-
tion of MAPK pathway occurs via mechanisms that are
largely independent of PLC activation and calcium re-
lease in both striatal neurons (Homer protein
dependent) and astrocytes (EGF receptor transactiva-
tion) [19,37,38]. The OGD-induced increase in ERK acti-
vation in astrocytes, as previously reported [39], did not
significantly change in presence of the mGluR5 antagon-
ist MPEP. Thus, it is possible that glutamate released in
response to OGD may activate alternative mGluR sub-
types that may be directly linked to the activation pro-
survival signal transduction pathways in astrocytes. Con-
sistent with this, mGluR3 is implicated in protecting
against astrocytes apoptosis following OGD [40].
Interestingly, the mGluR5-dependent activation of
PLC-mediated signaling leads to excessive calcium re-
lease and excitotoxic striatal neuronal death, which
could be prevented by the down regulation of Group I
mGluR expression following estradiol treatment [18].
Thus, a selective increase in PLC signaling likely corre-
lates with a pro-apoptotic role for astrocytic mGluR5,
as OGD-induced apoptosis is reduced in astrocytes
derived from mGluR5 null embryos. Moreover, selective
mGluR5 blockade has been reported to be neuroprotec-
tive [41]. Thus, it appears that increased mGluR5 sig-
naling in astrocytes might lead to cell death followingOGD-increased mGluR5a protein expression levels.
Interestingly, mGluR5 has been shown to be upregu-
lated in the spinal cord of ALS patients [22,24] and
astrocytic cell death in an amyotrophic lateral sclerosis
transgenic model has been shown to be attenuated by
blocking the mGluR5 receptor in vivo [42]. Moreover,
the disease onset was also delayed by this treatment.
Similarly, the brain permeable mGluR5 antagonist
MTEP provides neuroprotection in an in vivo ischemic
model [17].
Because the effect of the InsP3 receptor inhibitor Xes-
tospongin C on apoptosis is not observed in astrocytes
lacking the mGluR5, we have confirmed that the mGluR5-
PLC-InsP3-calcium signaling pathway is responsible for
induction of apoptosis by releasing calcium from intracel-
lular stores. As reviewed by Hanson et al. [43], calcium
released through InsP3 receptors is sequestered by mito-
chondria and mitochondrial calcium overload can induce
the apoptotic cascade. In addition, calcium release can
also stimulate calcium-sensitive enzymes such as the
phosphatase calcineurin, which is involved in other apop-
totic mechanisms [43]. Furthermore, we show that the for-
mation of a molecular complex between Homer proteins
and mGluR5 contributes to the activation of a pro-
apoptotic pathway, as the treatment of astrocytes with a
Tat-Homer interference peptide reduced OGD-induced
astrocytes apoptosis. This Tat-peptide was previously
shown to block mGluR5/Homer interactions but also
blocks Homer-dependent activation of ERK1/2 [19]. Thus,
although we did not observe reduced ERK1/2 phosphoryl-
ation in response to OGD following either MPEP treat-
ment or the loss of mGluR5 expression, it is possible that
mGluR5-dependent activation of the ERK1/2 pathway via
a Homer-dependent mechanism may also function to
antagonize mGluR5-mediated apoptosis of astrocytes that
is induced as the consequence of PLC-mediated mGluR5
signaling.
In conclusion, because of the neuroprotective role of
astrocytes, astrocytic cell death could have a huge im-
pact on acute or chronic neurodegenerative conditions.
Thus, targeting mGluR5-signaling pathway involved in
the induction of astrocyte apoptosis may have thera-
peutic benefits following ischemic insults such as stroke.
For example, selective blockade of mGluR5-dependent
PLC signaling in astrocytes might help limit cellular loss
in a variety of neurodegenerative diseases. In contrast,
the selective activation of mGluR5 G protein-mediated
PLC signaling might promote apoptotic cell death in
brain tumors, such as astrocytomas. This is of particular
importance considering that mutations in mGluR1a have
been associated with a variety of tumors, and that many
of the mutations bias receptor signaling via the activa-
tion of ERK1/2 at the expense of G protein signaling
[44-46] suggesting it may be possible to design biased
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2-Methyl-6-(phenylethynyl) pyridine hydrochloride (MPEP)
was purchased from Tocris Cookson (Ellisville, MO). All
cell culture reagents were from Invitrogen (Burlington,
ON). Cytotoxicity detection kit plus (lactose dehydrogen-
ase, LDH) was from Roche (Mississauga, ON). Rabbit
anti-mGluR5 antibodies were from Millipore (Billerica,
MA). Rabbit anti-phospho-p44/42ERK and anti-p44/42
ERK antibodies were from Cell Signaling Technology
(Danvers, MA). Rabbit anti-actin antibody was from Santa
Cruz Biotechnology (Santa Cruz, CA). Horseradish
peroxidase-conjugated anti-rabbit antibody, Dowex 1-X8
(formate form) resin with 200–400 mesh and Bradford
assay were purchased from Bio-Rad (Mississauga,
ON). Anti-mouse IgG secondary antibody and ECL
Western blotting detection reagents were from GE
Healthcare (Oakville, ON). myo-[3H]Inositol was acquired
from PerkinElmer Life Sciences (Waltham, MA). The
QuantiTect SYBR green single-step RT-PCR was from
Qiagen (Toronto, ON). Alexa-488 anti-mouse was pur-
chased from Molecular Probes (Burlington, ON). GenElute
Mammalian Total RNA miniprep kit, Hoechst 33342, (3-
(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT), Xestospongin C, and all other biochemical
reagents were purchased from Sigma-Aldrich (St. Louis,
MO). The Tat-peptides corresponding to the mGluR5 bind-
ing motif for Homer proteins (Homer peptide: YGRK
KRRQRRRALTPPSPFRDS and Scramble peptide: YGR
KKRRQRRRTRSLPSDPPAF [19] were purchased from
CanPeptide (Pointe Claire, PQ).
Animals
CD1 and BL6/129-Grm5tm1Rod/J [47] mice were pur-
chased from Charles River Labs and Jackson Laboratory,
respectively. Mice were housed in an animal care facility
at 23C on a 12 h light/12 h dark cycle with food and
water provided ad libitum. Animal care was in accord-
ance with the University of Western Ontario Animal
Care Committee.
Primary astrocyte cultures
Cortices were dissected from CD1 or BL6/129Grm5 in-
dividual littermate embryos (E15-16) and separated from
the striatum, as previously described [20]. After dissoci-
ation in D-MEM/glucose/10%FBS/Gentamycin/L-glu-
tamine media, the cells were plated onto poly-D-lysine
coated culture flasks and maintained at 37C and 5%
CO2. Plating media was replaced by fresh media the fol-
lowing day and every 4 days thereafter. At DIV 7, the
primary cultures were shaken overnight at 260 rpm at37C and washed three times with PBS to remove
microglia. Cells were allowed to recover in fresh media
and after 24 hours cells were trypsinized and re-plated
onto poly-D-lysine coated plates at a density of
12,000 cells/cm2. Experiments were performed at DIV
14-19. The purity of the astrocyte cultures was assessed
by immunocytochemistry with mouse anti-GFAP
(1:400) and Alexa-488 anti-mouse (1:500) by micros-
copy (with nuclear staining with Hoechst 33258) as
adapted from [48].
Oxygen/glucose deprivation experiments
After one wash with glucose/ L-glutamine-free D-MEM,
astrocyte cultures were incubated for different periods of
time with the same media in a hypoxic chamber (COY
Laboratory Products Inc.) at 37C, 5% CO2 and 0% O2,
as described previously [40]. Control cell plates (0 h)
were maintained in normoxic conditions. After OGD,
equal volume of DMEM/2X glucose/10%FBS/Gentamy-
cin/L-glutamine media was added to the cells. The
media of control astrocyte cultures was replaced by
equal volumes of D-MEM with 2X glucose and without
glucose. The cells were incubated at 37C, 5% CO2 for
24 h (reperfusion).
Western blotting
Cells were harvested either immediately after the incu-
bation in the hypoxic chamber (OGD), or after the 24 h
reperfusion period with RIPA buffer (10 mM Tris-HCl
pH=7.5, 140 mM NaCl, 1% Nonidet P-40, 1% sodium
deoxycholate, 0.1% SDS). After solublization, insoluble
material was removed by centrifugation and supernatant
was used to determine protein concentration by Brad-
ford assay. After dilution in SDS sample buffer, 75-
100 μg of protein was loaded into a 10% acrylamide
SDS-PAGE gel. After electrophoresis, proteins were
transferred to a nitrocellulose membrane. After blocking
non-specific binding with 10% non-fat milk in TBS with
0.05% Tween-20 (TBS-T), membranes were incubated
with rabbit anti-mGluR5 (1:4000), rabbit anti-actin
(1:10000), rabbit anti-phospho-pERK44/42 (1:1000), or
rabbit anti-pERK44/42 (1:1000, after anti-phosphoERK
stripping) antibodies overnight at 4C. After three
washes with TBS-T, blots were incubated 1 hour at room
temperature with HRP-conjugated anti-rabbit (1:10000)
or anti-mouse (1:5000) antibodies [20]. After three
washes with TBS-T, blots were developed with ECL and
exposed to films.
Quantitative real time reverse-transcript polymerase
chain reaction (qRT-PCR)
RNA samples were isolated with the GenElute Mamma-
lian Total RNA miniprep kit and treated with DNAse I
following the manufacturer instructions. 30 ng of total
Paquet et al. Molecular Brain 2013, 6:9 Page 9 of 11
http://www.molecularbrain.com/content/6/1/9RNA was used per reaction and mouse mGluR5 mRNA
and the mitochondrial ribosomal protein S12 (endogen-
ous housekeeping gene) mRNAs were amplified separ-




CATCCTTGG30 using the QuantiTect SYBR green single-
step RT-PCR kit as per manufacturers’ instructions. The
comparative Ct method (2–[delta][delta]Ct) was used for
quantification [49].
Inositol phosphate formation assay
Inositol lipids were radiolabeled by incubating the cor-
tical astrocyte cultures overnight with 1 μCi/ml myo-
[3H]inositol in D-MEM, as previously described by
Ribeiro et al. [20]. In brief, incorporated myo-[3H]inosi-
tol was removed by washing cells with Hank’s balanced
salt solution (HBSS). Cells were transferred in D-MEM
without glucose and placed in the hypoxic chamber or
not (0 h OGD control) for 4 h. After ischemia, LiCl was
added to the wells to achieve a final concentration of
10 mM and the cells were incubated for 30 min in pres-
ence or in absence of 10 μM MPEP. The reactions were
stopped on ice by the addition of 500 μl of perchloric
acid and then neutralized with 400 μl of 0.72 M KOH,
0.6 M KHCO3. Total [3H]inositol incorporated into cells
was determined by counting the radioactivity present in
50 μl of cell lysate. Total inositol phosphate was purified
from cell extracts by anion exchange chromatography
using Dowex 1-X8 (formate form) 200–400 mesh anion
exchange resin. [3H]Inositol phosphate formation was
determined by liquid scintillation.
MTT cell viability assay
After reperfusion, 1/10 of media volume of 5 mg/ml
MTT was added to the culture dishes and incubated at
37C, 5% CO2 for 3 h. The reaction was then stopped by
adding an equal volume of isopropanol. After trituration,
the crystal deposits (converted dye) were dissolved by
shaking for 20 min. Absorbances at 570 nm and 690 nm
(background) were read in triplicate and absorbance
values were corrected for the absorbance due to the cul-
ture media in absence of cells [50].
Hoechst staining
As described by Steckley et al., [49] Hoechst 33342 dye
was added in triplicate directly to live cells and incu-
bated for 30 min at 37C. The media was then removed
and the cells fixed in 3.7% formaldehyde for 60 min at
RT. After three PBS washes, the cells were kept at 4C
until imaged and apoptotic cells (condensed nuclei) were
quantified using ImageJ software. For each experimental
data point, 1000-2000 cells were counted from triplicatewells of sister cultures from at least 3 independent
experiments.
LDH release assay
After OGD/reperfusion experiments, lysis buffer
(10 mM Tris-HCl pH=7.5, 140 mM NaCl, 1% Nonidet
P-40, 1% sodium deoxycholate, 0.1% SDS) was added to
culture wells to determine the maximum LDH release.
After 15 min incubation at 37C and 5% CO2, 50 μl ali-
quots of triplicate samples or cell-free culture media
(background) were transferred to wells of a 96 well plate
containing 50 μl of PBS/well and experiments were per-
formed according to the manufacturer instructions
(Cytotoxicity detection kit plus, Roche). LDH release
was determined by absorbance (A492 nm-A690 nm) mea-
sured using a SPECTRAmax M5 plate reader and
expressed as percentage of the maximum release.
Data analysis
GraphPad Prism software was used to analyze data for
statistical significance and for curve fitting. Statistical
significance was determined by analysis of variance
(ANOVA) testing followed by post-hoc Multiple Com-
parison testing.
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